Ipamorelin
What to know about Ipamorelin
Ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. Human evidence is mostly pharmacology, not long-term outcome research.
- How it may work
- It activates the growth-hormone secretagogue receptor and can trigger a transient growth-hormone pulse. Selectivity observed in short studies does not prove long-term endocrine selectivity.
- What research found
- A small dose-escalation study in healthy men measured growth-hormone release and estimated an approximately two-hour terminal half-life after intravenous infusion.
- What is not settled
- Short pharmacology studies cannot define long-term glucose, fluid-balance, cardiovascular, pituitary, or immune risks.
- Research and product status
- Ipamorelin has no licensed U.S. product. Published human data do not establish broad outcome claims.
Research reference
- Research amount range
- 100–300 mcg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Intravenous in the cited evidence; formulation matters.
- Reported timing context
- Often before bed and/or fasted, to line up with natural growth-hormone pulses; food with fat blunts the pulse in research.
- What people report
- Sleep and recovery contexts are commonly discussed within the first weeks.
- Model accumulation timescale
- ~10 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
- Reported course context
- 8–12 weeks
- Reported break context
- 4 weeks Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- Human research measured an acute growth-hormone pulse and pharmacokinetics over hours. That biomarker response does not establish when sleep, recovery, muscle, or body-composition changes appear.
- When to assess
- No robust long-duration human outcome study provides an assessment week for commonly claimed goals. An immediate hormone rise is not a substitute for a measured functional outcome.
- Conditions and limitations
- The acute study does not validate bedtime use, fasting, exercise timing, or pairing with CJC-1295 as necessary for a meaningful human result.
- When to stop
- No evidence-based course length, maintenance phase, or quit rule has been established for the common off-label research use. Do not extend a run merely because expected subjective changes are absent.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about Ipamorelin alongside other compounds or medicines.
Key properties
- Formula
- C38H49N9O5
- Mol. weight
- 711.9 Da
- CAS
- 170851-70-4
- PubChem CID
- 9831659
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
The human study was a single intravenous dose measuring pharmacokinetics; the multi-week subcutaneous schedules in circulation are community-derived, so no schedule table is shown.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- GHRP / secretagogue pulsatility literatureGhrelin-mimetic GH release is pulsatile and synergises with GHRH analogs.